The American Urological Association (AUA), European Association of Urology (EUA) and International Urological Society (SIU) annual meetings were held in 2022. Studies on prostate cancer reported in the meetings mainly focus on the advances of diagnostic biomarkers (such as α-2, 3-1inked sialylation of terminal N-glycan on free PSA density, SelectMDx) and imaging techniques [such as multiparametric magnetic resonance imaging, prostate specific membrane antigen(PSMA)-PET/CT], the new method for prostate biopsy, the new treatments of prostate cancer including [177Lu] Ludotadipep and DROP-IN PSMA probe, and the prognosis assessment of prostate cancer (such as AR-V7). This article provides an overview on the research hotspots of three international academic meetings.
2022年美国泌尿外科学会年会、欧洲泌尿外科学会年会以及国际泌尿外科学会年会上针对前列腺癌相关研究的讨论主要集中在α-2，3位唾液酸糖基化前列腺特异性抗原密度百分比、SelectMDx等分子生物标志物，多参数磁共振、前列腺特异性膜抗原-正电子发射断层显像/计算机断层扫描等影像学评估方法，前列腺穿刺活检新方法在前列腺癌诊断方面的价值；小型前列腺特异性膜抗原、［177Lu］Ludotadipep探针等前列腺癌治疗方案的研究；以及雄激素受体剪接变体7等指标在前列腺癌患者预后评估中的价值等。本文围绕上述前列腺癌诊治的研究热点作一综述。.
Keywords: PSMA-PET/CT; Prostate biopsy; Prostate cancer; Prostate-specific antigen; Reviews.